LGALS3 and non-small cell lung carcinoma: Existing clinical trials are discovering new therapeutic combinations, studies such as GALLANT‐1, expect to explore the potential of the novel Gal‐3 inhibitor GB1211 (initially used as a treatment for cirrhosis) in advanced NSCLC, providing new approach for the management of advanced NSCLC.